Digital app to support AML patients during hospitalization
Official title: Multi-Site Randomized Controlled Trial of a Novel Digital Application (DREAMLAND) to Improve Outcomes for Patients with Acute Myeloid Leukemia
Funded at Massachusetts General Hospital · NIH-11365913 · Data updated 2026-11-12
A digital app called DREAMLAND is being tested to help people with acute myeloid leukemia feel better physically and emotionally during the first 4–6 weeks of hospitalization and chemotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 19, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $563,644 |
| NIH project number | 5R01CA288550-03 |
| Project ID | NIH-11365913 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with newly diagnosed AML who are hospitalized for intensive chemotherapy.
✕Less likely to help
Patients with AML who are not hospitalized or do not use digital tools may not experience the app’s benefits.
What this research studies
This project tests a self-administered app designed for AML patients facing intense treatment and hospitalization. The app includes modules for coping with diagnosis, learning about the illness, managing physical symptoms, and staying connected with support. Researchers will compare outcomes like quality of life and psychological well-being between patients who use the app and those receiving standard care. If successful, the app could be a scalable way to provide mental and emotional support during a demanding phase of AML treatment.
Why it matters
Potential benefit: If effective, DREAMLAND could improve mood, reduce distress, and enhance overall quality of life for AML patients during hospitalization.
How similar studies have gone: There is growing evidence that digital psychosocial tools can improve well-being in cancer patients, but specific AML-app trials are limited.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: El-Jawahri, Areej — Massachusetts General Hospital
- Study coordinator: El-Jawahri, Areej
Related research
Other NIH-funded projects on the same topics.
-
A Digital App to Help Patients with Acute Myeloid Leukemia
This project explores if a new digital app can help patients with acute myeloid leukemia feel better and improve their well-being.
-
A digital app to help patients with acute myeloid leukemia cope with their diagnosis and treatment.
This study is testing a new app called DREAMLAND that helps people with acute myeloid leukemia feel better emotionally and cope with the challenges of chemotherapy, making their hospital experience more supportive and positive.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.